OAM
RKDA icon

Oxford Asset Management’s Arcadia Biosciences RKDA Stock Holding History

Oxford Asset Management’s Portfolio RKDA Stock Details RKDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-874
Closed -$191K – 1071
2019
Q4 		$191K Buy
+874
New +$175K 0.01% 1558
2019
Q1 		– Sell
-557
Closed -$71K – 1928
2018
Q4 		$71K Buy
+557
New +$93.6K ﹤0.01% 1677

Other funds holding RKDA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.9B AUM 18.41% 1-Year Est. Return

Oxford Asset Management's RKDA Position: Q1 2020 in Review

Oxford Asset Management sold out of Arcadia Biosciences (RKDA) in Q1 2020, closing a stake of 874 shares — an estimated $191K sold.

Oxford Asset Management first reported a position in RKDA in Q4 2018 and held it in 2 quarters. The position peaked at $191K in Q4 2019. 12 funds tracked by Wall St. Rank hold RKDA as of Q1 2020.

  • Oxford Asset Management reported no remaining Arcadia Biosciences position as of Q1 2020 after selling out during the quarter.
  • Oxford Asset Management sold 874 Arcadia Biosciences shares in Q1 2020, an estimated $191K.
  • Oxford Asset Management first reported a position in Arcadia Biosciences in Q4 2018 and held it in 2 quarters.
  • Oxford Asset Management's Arcadia Biosciences position peaked at $191K in Q4 2019.
  • 12 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.